Patrys Limited · ASX:PAB
Patrys — Shareholder Meeting (November 2016)
18 slides from Patrys's shareholder meeting presentation, Nov 24, 2016
Slide 1: Annual General Meeting 2016
For personal use only Annual General Meeting 2016 Dr James Campbell CEO
Slide 2: Safe harbour statement
Safe harbour statement For personal use only The following material is for general informa4on purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of loss
Slide 3: Vision
Vision For personal use only Patrys is a biopharmaceutical company devoted to the development and commercialisation of novel antibody technologies to improve the clinical outcomes for cancer patients Annual General Meeting 2016 3
Slide 4: Snapshot
Snapshot For personal use only Exci4ng an4body (Ab) • Deoxymabs - in-licensed nuclear-penetra4ng Abs from Yale University plaWorms and pipeline • IgM plaWorm showing safety and signals of clinical efficacy • Both plaWorms offer mul4ple opportuni4es for development • Ability to generate new intellectual
Slide 5: Year in review
Year in review For personal use only • Completed a year of restructuring, rebranding, consolidation and building • Corporate costs reduced significantly • Closed German operations • Rationalised head office staffing • Migrated to technology-enabled virtual office • IgM program progressing via allian
Slide 6: Experienced leadership team
Experienced leadership team For personal use only • Board • John Read Chairman • James Campbell CEO & Managing Director • Mike Stork Non-Executive Director • Suzy Jones Non-Executive Director • Management • Dr James Campbell CEO & Managing Director • Melanie Leydin CFO & Company Secretary • Dr Deann
Slide 7: Development pipeline
Development pipeline For personal use only Product Discovery Preclinical Phase I Phase 2a (Target) PAT-SC1 Chinese rights (CD55) Gastric Cancer out-licensed PAT-SM6 Melanoma Multiple Myeloma Trial Deferred (GRP78) PAT-LM1 Licensing Solid Tumours candidate (NONO) Deoxymab Licensed from 3E10 Yale Univ
Slide 8: IgM assets
IgM assets For personal use only • Patrys’ IgM assets have shown anti-tumour activity in mice and in humans have shown a very good safety profile and signals of clinical efficacy • Natural human antibodies can be combined with existing chemotherapeutic treatments potentially without any cumulative t
Slide 9: Introducing Deoxymab 3E10
Introducing Deoxymab 3E10 For personal use only • Deoxymab 3E10 is a nuclear-penetrating lupus anti-DNA autoantibody with proven utility as a molecular delivery vehicle • 3E10 has previously been used in Phase 1 clinical trial for lupus • Anti-cancer application licensed from Yale University • First
Slide 10: Deoxymab 3E10 – Mechanism of action
Deoxymab 3E10 – Mechanism of action For personal use only Annual General Meeting 2016 10
Slide 11: Research partnered with Yale University
Research partnered with Yale University For personal use only • James E. Hansen, MD (Principal Investigator) • Assistant Professor, Department of Therapeutic Radiology, Yale School of Medicine • Physician-scientist and practicing radiation oncologist specializing in treatment of cancers of the brain
Slide 12: Multiple development paths for 3E10
Multiple development paths for 3E10 For personal use only Deoxymab 3E10 Combina4on with radia4on Single agent for targeted Combina4on with chemotherapy therapy for radioresistant therapy of malignancies for chemo-resistant tumors and/ tumors and/or to reduce the with defects in DNA repair, or to red
Slide 13: Deoxymab 3E10 enhances radiotherapy
Deoxymab 3E10 enhances radiotherapy For personal use only 3E10 scFv radiosensi4ses U87 human glioma cells, but is not toxic to unirradiated cells Hansen et al., (2012) Science Transla.onal Medicine, 4(157): 157ra142. Annual General Meeting 2016 13
Slide 14: Deoxymab 3E10 enhances chemotherapy
Deoxymab 3E10 enhances chemotherapy For personal use only Using U87 human glioma cells Deoxymab 3E10 enhances chemotherapy which causes DNA damage (Doxorubicin), but not chemotherapy that doesn’t affect DNA (Paclitaxel) Doxorubicin Paclitaxel % Dead cells nM % Dead cells nM Hansen et al., (2012) Sci
Slide 15: Deoxymab 3E10 single agent efficacy
Deoxymab 3E10 single agent efficacy For personal use only Deoxymab 3E10 decreases tumour growth in BRCA2- deficient CAPAN-1(pancrea4c) xenograis Noble et al. (2015). Cancer Research. 75(11): 2285-91. Annual General Meeting 2016 15
Slide 16: Deoxymab 3E10 development milestones
Deoxymab 3E10 development milestones For personal use only File IND 9 Pre-IND Mee7ng with FDA 8 File Orphan Drug Applica7on 7 Safety Pharmacology Completed 6 Tox Program Completed 5 Stability completed 4 Comple7on of cGMP Manufacturing 3 Potency Studies at Yale 2 Complete An7body Humaniza7on 1 Annua
Slide 17: The year ahead
The year ahead For personal use only • Comple4on of in silico design and op4miza4on of Deoxymab 3E10 ✓ • Preclinical tes4ng of mul4ple Deoxymab 3E10 candidates ✓ • Lead candidate selec4on for Deoxymab 3E10 program • Preclinical data and publica4ons on Abs and targets • Ongoing development of PAT-SC1
Slide 18: Further information
Further information For personal use only Dr James Campbell, CEO and Managing Director Ph: +61 3 9670 3273 Email: info@patrys.com Website: www.patrys.com Annual General Meeting 2016 19